Euronews is no longer accessible on Internet Explorer. This browser is not updated by Microsoft and does not support the last technical evolutions. We encourage you to use another browser, such as Edge, Safari, Google Chrome or Mozilla Firefox.

AstraZeneca's Tagrisso gets China OK for type of lung cancer

AstraZeneca's Tagrisso gets China OK for type of lung cancer
FILE PHOTO: A sign is seen at an AstraZeneca site in Macclesfield, England, May 19, 2014. REUTERS/Phil Noble -
Phil Noble(Reuters)
Euronews logo
Text size Aa Aa

(Reuters) – AstraZeneca Plc <AZN.L> said on Wednesday it had received marketing authorisation from China’s National Medical Products Administration for its top-selling drug, Tagrisso, to treat adults with a form of lung cancer.

China approved Tagrisso as a first-line treatment for adults with non-small cell lung cancer patients whose tumours have certain genetic mutations, AstraZeneca said.

Last month, the British drugmaker said a late-stage study showed Tagrisso had significantly helped patients with epidermal growth factor receptor-mutated metastatic non-small cell lung cancer live longer without the disease worsening.

The company has moved deeper into cancer therapy through wide-ranging deals, including those for immunotherapy and targeted therapy. Earlier this year, it agreed to a multi-billion dollar oncology deal with Japan’s Daiichi Sankyo Co <4568.T>.

Sales from AstraZeneca’s oncology unit soared 57% to $2.17 billion in the second quarter, accounting for 38% of total product sales, with revenue from Tagrisso nearly doubling to $784 million.

AstraZeneca had also raised its product sales forecast for 2019, thanks in part to strong sales of cancer drugs.

(Reporting by Noor Zainab Hussain in Bengaluru; Editing by Bernard Orr)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on for a limited time.